AP26113

Ariad Pharma's lung cancer drug gets breakthrough therapy status
Yahoo/AP
Thu, 10/2/14 - 08:04 am
Ariad Pharmaceuticals
AP26113
FDA
lung cancer
breakthrough therapies
Ariad Pharma Short Seller Explains Why Takeover Rumor is Bunk
TheStreet.com
Mon, 01/27/14 - 12:20 pm
Ariad Pharmaceuticals
M&A
AP26113
Eli Lilly
Iclusig
Opportunities in Lung Cancer Therapies
Motley Fool
Sun, 11/24/13 - 12:30 pm
lung cancer
non-small cell lung cancer
Avastin
Genentech
Roche
Tarceva
AstraZeneca
Iressa
Alimta
selumetinib
Array Biopharma
CO-1686
Clovis Oncology
AP26113
Ariad Pharmaceuticals
ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with Non-Small Cell Lung Cancer
Yahoo/BusinessWire
Sat, 09/28/13 - 11:57 am
non-small cell lung cancer
Ariad Pharmaceuticals
AP26113
Ariad Pharma denied FDA's coveted 'breakthrough' stamp for lung cancer drug
Fierce Biotech
Fri, 08/9/13 - 10:00 am
Ariad Pharmaceuticals
FDA
non-small cell lung cancer
AP26113
Scrappy Upstarts Aiming For Pfizer's Xalkori Market
Seeking Alpha
Mon, 06/3/13 - 11:29 am
Pfizer
Xalkori
Tesaro
Ariad Pharmaceuticals
AP26113
lung cancer
TSR-011
3 Things to Watch at Ariad Pharmaceuticals
Motley Fool
Tue, 10/16/12 - 10:38 am
Ariad Pharmaceuticals
Ponatinib
ridaforolimus
AP1903
AP26113
ARIAD Presents Initial Clinical Proof-of-Concept of AP26113 in Patients with Non-Small Cell Lung Cancer at ESMO 2012 Congress
Yahoo/BusinessWire
Sat, 09/29/12 - 12:02 pm
non-small cell lung cancer
Ariad Pharmaceuticals
AP26113